Patent: 6,228,620
Summary for Patent: 6,228,620
| Title: | Protein complexes having factor VIII:C activity and production thereof |
| Abstract: | Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an alpha1-antitrypsin signal sequence. |
| Inventor(s): | Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson |
| Assignee: | GSK Vaccines SRL , Novartis Vaccines and Diagnostics Inc |
| Application Number: | US08/441,943 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,228,620
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | HELIXATE FS, KOGENATE, KOGENATE FS | antihemophilic factor (recombinant) | For Injection | 103332 | August 20, 2002 | 6,228,620 | 2018-05-08 |
| Bayer Healthcare Llc | HELIXATE FS, KOGENATE, KOGENATE FS | antihemophilic factor (recombinant) | For Injection | 103332 | June 7, 2007 | 6,228,620 | 2018-05-08 |
| Bayer Healthcare Llc | HELIXATE FS, KOGENATE, KOGENATE FS | antihemophilic factor (recombinant) | For Injection | 103332 | July 31, 2009 | 6,228,620 | 2018-05-08 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
